Locally advanced NSCLC: oral vinorelbine shows better safety profile than etoposide
- 13.07.2016
- Onkologie
- Online-Artikel
The randomised, multicentre, open-label, phase II RENO trial was conducted with the objective of establishing a standard chemotherapy regimen in the setting of chemo-radiotherapy of locally advanced NSCLC. A total of 134 patients with inoperable stage III NSCLC received either oral vinorelbine plus cisplatin or etoposide plus cisplatin.